Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Current Leases (2019 - 2026)

Kiniksa Pharmaceuticals International filings provide 7 years of Current Leases readings, the most recent being $3.2 million for Q1 2026.

  • On a quarterly basis, Current Leases rose 38.31% to $3.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $3.2 million, a 38.31% increase, with the full-year FY2025 number at $3.0 million, up 49.87% from a year prior.
  • Current Leases hit $3.2 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $3.0 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $3.5 million in Q1 2023 to a low of $2.0 million in Q4 2024.
  • Median Current Leases over the past 5 years was $2.5 million (2025), compared with a mean of $2.7 million.
  • Biggest five-year swings in Current Leases: crashed 34.55% in 2024 and later surged 49.87% in 2025.
  • Kiniksa Pharmaceuticals International's Current Leases stood at $3.3 million in 2022, then tumbled by 31.75% to $2.3 million in 2023, then dropped by 11.54% to $2.0 million in 2024, then skyrocketed by 49.87% to $3.0 million in 2025, then rose by 6.13% to $3.2 million in 2026.
  • The last three reported values for Current Leases were $3.2 million (Q1 2026), $3.0 million (Q4 2025), and $2.7 million (Q3 2025) per Business Quant data.